Premium
Effect of azelnidipine on sympathetic nerve activity and baroreflex control in the patients with hypertension
Author(s) -
Kishi Takuya
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.lb120-a
Subject(s) - baroreflex , medicine , heart rate variability , blood pressure , cardiology , heart rate , autonomic nerve , sympathetic activity , anesthesia
A new long‐acting L‐type Calcium channel blocker, azelnidipine, is reported not to increase the heart rate. However, it has not been determined whether long‐term treatment of azelnidipine for hypertension in human has the effects on sympathetic nerve activity and baroreflex sensitibity (BRS) or not. The aim of this study was to determine the effect of azelnidipine on sympathetic nerve activity and BRS. We studied 10 hypertensive patients treated with 8–16mg azelnidipine. Before the treatment and 3 months after the treatment, we measured the blood pressure (BP), BRS (in Tilt test), heart rate variability (HRV), and BP variability (BPV). After 3 months, systolic BP and the null low‐frequency component of systolic BPV (LFnuSBP), as the parameter of sympathetic nerve activity, were significantly decreased (SBP;158±10 to 124±6mmHg, LFnuSBP;58±4 to 50±3%, n=10, P<0.05). The high‐frequency component of HRV, as the parameter of parasympathetic nerve activity, was not significantly changed. BRS, which was impaired in the patients with hypertension, was significantly improved (13.2±2.8 to 19.6±4.1ms/mmHg, n=10, P<0.05). These results suggest that 3 months treatment with azelnidipine for hypertension has the sympatho‐inhibtory effect and improve the baroreflex control.